TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30870252

Group type: EXPERIMENTAL
Intervention: cherry extract
Number of subjects: 84

Group type: COMPARATOR
Intervention: dietitian-assisted diet modification
Number of subjects: 84

Group type: COMPARATOR
Intervention: diet modification
Number of subjects: 84
Study: 29157789

Group type: EXPERIMENTAL
Intervention: Mobile phones in 'on' mode for 15 minutes (exposed to 900-1800MHz EMW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mobile phones in 'off' mode for 15 minutes
Number of subjects: 30
Study: 26725548

Group type: EXPERIMENTAL
Intervention: Chant Talk
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pitch Inflections
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 24821586

Group type: EXPERIMENTAL
Intervention: linagliptin 5mg daily
Number of subjects: 2701

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2701
Study: 22552566

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg a day
Number of subjects: 25620

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg a day
Number of subjects: 25620

Group type: EXPERIMENTAL
Intervention: Combination therapy (ramipril 10 mg + telmisartan 80 mg)
Number of subjects: 25620
Study: 20084279

Group type: EXPERIMENTAL
Intervention: SNPs associated with CIN3/cancer: OAS3 rs12302655, SULF1 rs4737999, IFNG rs11177074, DUT rs3784621, DMC1 rs5757133, GTF2H4 rs2894054, EVER1/EVER2 rs9893818
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: SNPs for OAS3, SULF1, DUT, and GTF2H4
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: IFNG and EVER1/EVER2 SNPs
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Control group (random controls)
Number of subjects: 1167
Study: 18711936

Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisolone 40 mg daily tapered to 5 mg over 12 weeks) + MB-MDT
Number of subjects: 400

Group type: COMPARATOR
Intervention: MB-MDT only
Number of subjects: 400
Study: 17045906

Group type: COMPARATOR
Intervention: Inhaled treprostinil at 7.5 mug
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil at 30 mug
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil at 15 mug with varying pulses (18, 9, 3, 2, 1)
Number of subjects: 123
Study: 14530421

Group type: EXPERIMENTAL
Intervention: Medium-spaced elastomeric chain
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nickel titanium coil springs
Number of subjects: 22
Study: 10894582

Group type: EXPERIMENTAL
Intervention: Propofol (20‐120 mg) and fentanyl (0.25‐1.5 mg)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Midazolam (2‐6 mg) and meperidine (25‐75 mg)
Number of subjects: 274
Study: 8667091

Group type: EXPERIMENTAL
Intervention: Physician communication intervention (4.5 hours of training on eliciting and responding to patients' concerns)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Physician communication intervention
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (4.5 hours of training in medical decision-making)
Number of subjects: 348
Study: 1545092

Group type: EXPERIMENTAL
Intervention: Maternal elimination diet (abstaining from cow's milk and egg from gestational week 28 to delivery)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Normal food during pregnancy (control group)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Maternal elimination diet
Number of subjects: 198
Study: 3904410

Group type: EXPERIMENTAL
Intervention: Clonidine detoxification
Number of subjects: 39

Group type: COMPARATOR
Intervention: Slow tapering of methadone
Number of subjects: 39
Study: 31985746

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with mean arterial blood pressure (MABP) less than 70 mm Hg for a minimum of 10 minutes
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with mean arterial blood pressure (MABP) less than 70 mm Hg for a continuous episode of minimum 20 minutes
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with mean arterial blood pressure (MABP) greater than 90 mm Hg for a minimum of 45 minutes
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with mean arterial blood pressure (MABP) greater than 90 mm Hg for a continuous episode of minimum 115 minutes
Number of subjects: 365
Study: 28971973

Group type: EXPERIMENTAL
Intervention: Standard care plus rehabilitation (3-month multimodal hybrid inpatient-outpatient motivation, exercise and nutrition rehabilitation programme, in addition to non-invasive ventilation)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 37
Study: 27234601

Group type: EXPERIMENTAL
Intervention: Pictograph-enhanced discharge instructions
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 144
Study: 24872027

Group type: EXPERIMENTAL
Intervention: Nicotine oral spray (1mg of nicotine free base per spray) plus nicotine patch
Number of subjects: 1423

Group type: COMPARATOR
Intervention: Placebo spray plus nicotine patch
Number of subjects: 1423
Study: 23649050

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg every 8 hours for 3 days
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Serratiopaptidase 10 mg every 8 hours for 3 days
Number of subjects: 110
Study: 20819867

Group type: EXPERIMENTAL
Intervention: Complex tasks with interruptions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Simple tasks with interruptions
Number of subjects: 32

Group type: COMPARATOR
Intervention: All prescribing tasks
Number of subjects: 32
Study: 18524271

Group type: EXPERIMENTAL
Intervention: Formocresol pulpotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Root canal therapy (RCT)
Number of subjects: 50
Study: 15828615

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogens alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRT cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal dose of estrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRT indication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultra-sonography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast surveillance
Number of subjects: 0
Study: 12461301

Group type: EXPERIMENTAL
Intervention: Chlorthalidone, 12.5-25 mg/d (n=15,255)
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Amlodipine, 2.5-10 mg/d (n=9048)
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Lisinopril, 10-40 mg/d (n=9054)
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 33357
Study: 10492100

Group type: EXPERIMENTAL
Intervention: Intensive regimen (3000 microg dinoprostone given three times daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard regimen (3000 microg dinoprostone once daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intensive regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 100
Study: 8758286

Group type: EXPERIMENTAL
Intervention: Oral artemether (Art) 6 mg/kg followed by 3 repeated doses every 15 days
Number of subjects: 741

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 741
Study: 1861474

Group type: EXPERIMENTAL
Intervention: Type B music (soft, slow, easy-listening, popular music)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Type A music (loud, fast, exciting, popular music)
Number of subjects: 24
Study: 6688500

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone sodium phosphate (0.6 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 30514113

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NMES application
Number of subjects: 60
Study: 30253035

Group type: EXPERIMENTAL
Intervention: Alt‐RAMEC/FM
Number of subjects: 34

Group type: COMPARATOR
Intervention: RME/FM
Number of subjects: 34
Study: 30351691

Group type: EXPERIMENTAL
Intervention: Controlled halotherapy (10 procedures with sodium chloride dry aerosol)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 73
Study: 23947690

Group type: EXPERIMENTAL
Intervention: Topical Arnica
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 22918608

Group type: EXPERIMENTAL
Intervention: Natural view presentation with minimum delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural view presentation with delay (33 to 150 ms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mirror-reversed and/or inverted views
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrete movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dominant hand movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-dominant hand movements
Number of subjects: 0
Study: 21225519

Group type: EXPERIMENTAL
Intervention: Treadmill training with biofeedback function
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (rehabilitation regime without treadmill exercises)
Number of subjects: 0
Study: 17332278

Group type: COMPARATOR
Intervention: Sunitinib for GIST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunitinib for advanced renal cell carcinoma
Number of subjects: 0
Study: 15377314

Group type: EXPERIMENTAL
Intervention: 16 U botulinum toxin A in the frontal muscles and placebo in the neck muscles
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin A in the frontal and neck muscles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo in the frontal and neck muscles
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 16 U botulinum toxin A
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin A
Number of subjects: 60
Study: 11196518

Group type: EXPERIMENTAL
Intervention: Individually attended treatment
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Small group format program
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 126
Study: 9643397

Group type: EXPERIMENTAL
Intervention: Inborn status (delivery in a tertiary care facility)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Multiple pregnancies
Number of subjects: 202

Group type: COMPARATOR
Intervention: Presence of a hospital staff paediatrician in the delivery room
Number of subjects: 202
Study: 7977319

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (50 U/kg subcutaneously three times weekly)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (treatment group)
Number of subjects: 83
Study: 2493536

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30700564

Group type: EXPERIMENTAL
Intervention: Continuous Infusion of Vancomycin (CIV)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intermittent Infusion of Vancomycin (IIV)
Number of subjects: 104
Study: 28437506

Group type: EXPERIMENTAL
Intervention: Proximal Femur Nail (PFN)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Proximal Femur Locking Compression Plate (PFLCP)
Number of subjects: 48
Study: 25556080

Group type: EXPERIMENTAL
Intervention: Clozapine (n = 49)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Quetiapine (n = 15)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Olanzapine (n = 19)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Risperidone (n = 16)
Number of subjects: 99
Study: 23099220

Group type: EXPERIMENTAL
Intervention: Potassium nitrate supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21773588

Group type: EXPERIMENTAL
Intervention: Chicory inulin (20 g day(-1))
Number of subjects: 12
Study: 19845240

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lorazepam 0.5 mg
Number of subjects: 80
Study: 16123923

Group type: EXPERIMENTAL
Intervention: Ultrasound examination by examiner A
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Ultrasound examination by examiner B
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Ultrasound examination by both examiners
Number of subjects: 239
Study: 10355845

Group type: EXPERIMENTAL
Intervention: Fat emulsion (30% of total calories) administered from day of operation to POD 7
Number of subjects: 17

Group type: COMPARATOR
Intervention: Glucose as a non-protein calorie source administered from day of operation to POD 7
Number of subjects: 17
Study: 7491136

Group type: EXPERIMENTAL
Intervention: Metronidazole and erythromycin
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 2031364

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide
Number of subjects: 133

Group type: COMPARATOR
Intervention: Graduated compression bandages (control)
Number of subjects: 133
Study: 7213520

Group type: EXPERIMENTAL
Intervention: Heroin (3 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heroin (6 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heroin (12 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heroin (3, 6, 12 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Morphine (20 mg/70 kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31743394

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 103
Study: 31022102

Group type: EXPERIMENTAL
Intervention: Tobacco communication evidence-based practice implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobacco policy and program implementation
Number of subjects: 0
Study: 30278495

Group type: EXPERIMENTAL
Intervention: 40 mL of 0.375% ropivacaine mixed with 1 μg/kg dexmedetomidine (group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 40 mL of 0.375% ropivacaine (group C)
Number of subjects: 60
Study: 26499503

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by a certified diabetes-educator pharmacist
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 100
Study: 25172514

Group type: EXPERIMENTAL
Intervention: Integrated Management of Neonatal and Childhood Illness intervention
Number of subjects: 60480
Study: 22126894

Group type: EXPERIMENTAL
Intervention: Etomidate (ER)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Propofol (PR)
Number of subjects: 33
Study: 20616786

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist intervention group
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 17289888

Group type: EXPERIMENTAL
Intervention: PCA3 urine test
Number of subjects: 583

Group type: COMPARATOR
Intervention: Serum PSA
Number of subjects: 583
Study: 15781340

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell collection (PBSCC) and autologous stem cell transplantation (ASCT)
Number of subjects: 14
Study: 12815800

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy with at least three drugs
Number of subjects: 75
Study: 9813401

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 2,400 mg/day)
Number of subjects: 18
Study: 7712303

Group type: EXPERIMENTAL
Intervention: 20 g sorbitol and 20 g glucose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 g sorbitol and 9 g lipids
Number of subjects: 14

Group type: COMPARATOR
Intervention: 20 g sorbitol alone
Number of subjects: 14
Study: 2540650

Group type: EXPERIMENTAL
Intervention: Timolol (5 mg twice daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study: 30528828

Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg twice daily (APR40)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily (APR30)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 28174196

Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 350

Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 350
Study: 25263246

Group type: EXPERIMENTAL
Intervention: Electromagnetic computer assisted surgical technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 200
Study: 23591293

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isocaloric moderate-intensity continuous exercise (MICE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study: 21372124

Group type: EXPERIMENTAL
Intervention: Sagopilone 16 mg/m² as a 3-h i.v. infusion every 21 days for up to 6 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sagopilone 16 mg/m² as a 0.5-h i.v. infusion every 21 days for up to 6 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sagopilone (both infusion schedules)
Number of subjects: 63
Study: 19998333

Group type: EXPERIMENTAL
Intervention: Imagining group (IG) - used a computer-imaging program (HAAIR) to simulate baldness and wig use
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standardized Care group (SCG) - directed to a resource room for women with chemotherapy-related alopecia
Number of subjects: 45
Study: 17125995

Group type: EXPERIMENTAL
Intervention: Colloid preload before spinal anesthesia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Crystalloid preload before spinal anesthesia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Colloid preload before combined spinal-epidural anesthesia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Crystalloid preload before combined spinal-epidural anesthesia
Number of subjects: 200
Study: 16393218

Group type: EXPERIMENTAL
Intervention: 60 mg of ketorolac trometamol (KT) administered intravenously as premedication 30 min prior to procedure
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (normal saline) administered intravenously as premedication 30 min prior to procedure
Number of subjects: 140
Study: 11925518

Group type: EXPERIMENTAL
Intervention: High dose (400% above the seizure threshold) right unilateral (RUL) ECT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderate dose (150% above seizure threshold) RUL ECT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low dose (just above seizure threshold) bifrontal (BF) ECT
Number of subjects: 24
Study: 9464674

Group type: EXPERIMENTAL
Intervention: In-house referral by general practitioners to a colleague in the practice for review of hospital care need
Number of subjects: 8
Study: 7647379

Group type: EXPERIMENTAL
Intervention: Pulsatile flow during cardiopulmonary bypass
Number of subjects: 2

Group type: COMPARATOR
Intervention: Continuous flow during cardiopulmonary bypass
Number of subjects: 2
Study: 2667310

Group type: EXPERIMENTAL
Intervention: Urapidil (25 or 50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 55890

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methimazole 40 mg per day
Number of subjects: 24
Study: 31011912

Group type: EXPERIMENTAL
Intervention: Sex Positive! video-based web intervention
Number of subjects: 830

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 830
Study: 28244906

Group type: EXPERIMENTAL
Intervention: Weekly teriparatide administration for 6 months postoperatively
Number of subjects: 75

Group type: COMPARATOR
Intervention: No teriparatide (control arm)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Weekly teriparatide administration
Number of subjects: 75
Study: 25304755

Group type: EXPERIMENTAL
Intervention: Repeated dose 4+8+4mg betamethasone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Single dose 16mg betamethasone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no betamethasone)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Betamethasone (both doses)
Number of subjects: 37
Study: 23510092

Group type: EXPERIMENTAL
Intervention: Combined HBO2/NBH (60 minutes of HBO2 at 1.5 ATA followed by 3 hours of NBH at 100% FiO2 at 1.0 ATA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined HBO2/NBH
Number of subjects: 42
Study: 21223344

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks (q4w)
Number of subjects: 0
Study: 19947366

Group type: EXPERIMENTAL
Intervention: Combination therapy (including mastectomy, neoadjuvant and adjuvant chemohormonal and radiotherapy)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 444
Study: 17854247

Group type: EXPERIMENTAL
Intervention: Combination of zonisamide and bupropion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Zonisamide alone
Number of subjects: 18
Study: 15167990

Group type: EXPERIMENTAL
Intervention: TVT (Tension-free Vaginal Tape)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 200
Study: 11304902

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg p.o. bid
Number of subjects: 12

Group type: COMPARATOR
Intervention: No alosetron
Number of subjects: 12
Study: 9219782

Group type: EXPERIMENTAL
Intervention: Stonetome combination catheter
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional sphincterotomy with separate balloon sweep
Number of subjects: 17
Study: 7902021

Group type: EXPERIMENTAL
Intervention: Deflazacort 30 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deflazacort 60 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deflazacort 6 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3650597

Group type: COMPARATOR
Intervention: Questionnaire only
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Bogus-pipeline only
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Bogus-pipeline with saliva collection
Number of subjects: 191